The Pharmacy Times® Lung Cancer Resource Center is a comprehensive resource for clinical news and expert insights on issues related to cancer that begins on the lungs, including non-small cell lung cancer and small cell lung cancer.
April 25th 2024
A 76% lower risk was displayed with adjuvant alectinib compared to chemotherapy treatment for non–small cell lung cancer.
Background and Key Concepts in Biosimilars: Improving Awareness and Addressing Common Concerns
1.0 Credit / Law
View More
Clinical Conversations With the Cancer Care Team: Striving for Equitable Access to Oral Anticancer Medications
1.5 Credits / Law, Oncology
View More
Mastering Oncology Clinical Trials: Immune Checkpoint Inhibitors in Frontline Metastatic Non–Small Cell Lung Cancer
1.5 Credits / Lung Cancer, Oncology
View More
Child Abuse: Responsibilities and Protection of the Reporter
1.0 Credit / Law
View More
Phase 3 Trial of Pembrolizumab with Olaparib Did Not Meet Endpoints Among Individuals with NSCLC
March 26th 2024Pembrolizumab in combination with chemotherapy followed by maintenance olaparib did not meet its pre-specified statistical criteria of overall survival or progression free survival.
Read More
FDA Grants Breakthrough Therapy Designation to NVL-520 for ROS1-Positive NSCLC
February 28th 2024NVL-520 is a novel brain-penetrant ROS1-selective TKI being investigated for ROS1-positive metastatic non–small cell lung cancer in patients who have previously been treated with 2 or more ROS1 TKIs.
Read More
Advancing Pharmacists’ Role in Personalized Treatment for Breast, Prostate, and Lung Cancer
Precision oncology represents an evolution in therapeutic practice.
Read More
Researchers Connected Radon, A Known Cause of Lung Cancer, to Additional Health Condition
January 10th 2024Individuals with ischemic stroke that resided in areas with an indoor radon concentration greater than 4 pCi/L had an increased risk of developing clonal hematopoiesis of indeterminate potential.
Read More